好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Multifield Extended High-Definition Transcranial Direct Current Stimulation (MFE HD-tDCS) in Mild Cognitive Impairment (MCI): Effects on Cognition and Brain Network Connectivity.
Aging, Dementia, and Behavioral Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
3-011

To investigate the feasibility of a novel multi-field (four regions), extended (80-minute sessions) approach to HD-tDCS combined with Computerized Cognitive Training (CCT); to begin exploring its effects on cognition and on brain functional connectivity, including cortical-hippocampal changes. 

Early treatment of MCI could delay cognitive decline. With customized protocols noninvasive neuromodulation could help restore the brain’s plastic properties while a higher total dose delivered might translate into larger behavioral gains. Moreover, stimulation of the dominant lateral parietal cortex has been shown to modulate cortical-hippocampal networks and enhance associative memory in healthy young and older adults.  

Double-blinded, randomized trial of daily sham HD-tDCS + CCT (n=4) or anodal HD-tDCS + CCT (n = 4) for 15 sessions over 3 months. We targeted four cortical regions using neuronavigation: putative frontal coordinates of cognitive reserve, and lateral parietal coordinates with a hypothesized robust connection to the hippocampus. Neurocognitive outcomes were assessed at 3 and 6 months and resting connectivity changes at 3 months. Analysis used Wilcoxon-rank sum tests and Bonferroni correction for multiple comparisons. 

All completed the trial with minor side effects. Blinding was successful. We found a larger increase in ADCS-PACC at 6 months for Anodal (65%) compared to Sham (14%), but not statistically significant.  The anodal treatment was associated with a lowering of depression and anxiety (p=0.018). Importantly, the Anodal group trended towards higher depression (p=0.059) and Anxiety (p=0.078) at baseline. Anodal stimulation was associated with a decline in left Parietal Cortex-left Caudal Hippocampus connectivity compared to Sham (p=0.042). 

The intervention was well tolerated.  Results should be interpreted   with caution given the small sample size.  Modulation of the left cortical-hippocampal network replicates prior key results in healthy populations. Findings might represent a normalization of an aberrant and/or compensatory hyperconnectivity previously described in MCI. Larger studies are needed to further elucidate these findings. 

 

Authors/Disclosures
Abigail K. Peterson
PRESENTER
Miss Peterson has received research support from NIH .
Elias Granadillo, MD (Medical College of Wisconsin) Dr. Granadillo has nothing to disclose.
Emilie Bloyer, BS Miss Bloyer has nothing to disclose.
Laura Hancock, PhD Dr. Hancock has received personal compensation in the range of $5,000-$9,999 for serving as a educator with Can Do MS (non-profit).
Priyanka P. Shah-Basak, PhD (Medical College of Wisconsin) The institution of Dr. Shah-Basak has received research support from NIH NIDCD. The institution of Dr. Shah-Basak has received research support from NIH NIDCD.
Sara Pillay, PhD Dr. Pillay has nothing to disclose.
Peter Kraegel, MA Mr. Kraegel has nothing to disclose.
Shelby Schold Ms. Schold has nothing to disclose.
Ozioma Okonkwo, PhD Prof. Okonkwo has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for INS. The institution of Prof. Okonkwo has received research support from NIH.
Veena A. Nair, PhD (DEPT. OF RADIOLOGY , UW MADISON) The institution of Dr. Nair has received research support from NIH.
Vivek Prabhakaran, MD (University of Wisconsin) Dr. Prabhakaran has nothing to disclose.
Hrissanthi Ikonomidou, MD, PhD (University of Wisconsin, Child Neurology) An immediate family member of Dr. Ikonomidou has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for RNN Journal. An immediate family member of Dr. Ikonomidou has stock in Solvay. Dr. Ikonomidou has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with NIH, FDA.